Teva Pharmaceutical Industries Limited Presented New Data From Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society

Published: Apr 17, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Reproductive Society (PCRS).

Back to news